Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
Express Scripts
McKesson
AstraZeneca
Medtronic

Last Updated: October 16, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR RAVICTI

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Ravicti

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01347073 Study of the Safety, Pharmacokinetics and Efficacy of HPN-100, in Pediatric Subjects With Urea Cycle Disorders (UCDs) Completed Horizon Pharma Ireland, Ltd., Dublin Ireland Phase 3 2011-07-01 This non-randomized, open-label study was approximately one year in duration and consisted of a short term NaPBA to HPN-100 switchover part involving two overnight stays followed by a 12-month long term treatment period involving monthly visits.
NCT01881984 Use of Ravicti™ in Patients With MCAD Deficiency With the 985A>G (K304E) Mutation Completed Horizon Pharma Ireland, Ltd., Dublin Ireland Phase 1 2013-06-01 This is a medical research study to test a medication in adult patients with a disease called medium-chain acyl-CoA dehydrogenase (MCAD) deficiency caused by at least one copy of the 985A>G mutation. The medication is glycerol phenylbutyrate, called Ravicti, which is currently FDA approved for the treatment of urea cycle disorders. Previous research suggests that Ravicti may also be effective in the treatment MCAD deficiency. This study will investigate the safety and efficacy (how well it works) of Ravicti in patients with MCAD deficiency caused by having at least one copy of the 985A>G mutation.
NCT01881984 Use of Ravicti™ in Patients With MCAD Deficiency With the 985A>G (K304E) Mutation Completed University of Pittsburgh Phase 1 2013-06-01 This is a medical research study to test a medication in adult patients with a disease called medium-chain acyl-CoA dehydrogenase (MCAD) deficiency caused by at least one copy of the 985A>G mutation. The medication is glycerol phenylbutyrate, called Ravicti, which is currently FDA approved for the treatment of urea cycle disorders. Previous research suggests that Ravicti may also be effective in the treatment MCAD deficiency. This study will investigate the safety and efficacy (how well it works) of Ravicti in patients with MCAD deficiency caused by having at least one copy of the 985A>G mutation.
NCT01949766 Transition From Buphenyl to RAVICTI for the Therapy of Byler Disease No longer available University of Pittsburgh N/A 1969-12-31 This is a single patient compassionate use protocol to determine whether RAVICTI will improve bile flow in a subject who previously tolerated therapy with Buphenyl.
NCT02046434 Phenylbutyrate Response as a Biomarker for Alpha-synuclein Clearance From the Brain Active, not recruiting University of Colorado, Denver Phase 1 2014-01-01 This is a Phase I clinical trial of the FDA approved drug Glycerol Phenylbutyrate to see if phenylbutyrate can increase the removal of alpha-synuclein from the brain into the bloodstream. Alpha-synuclein forms abnormal protein deposits in dopamine neurons and is believed to cause the death of brain cells, leading to Parkinson's Disease.
NCT02094222 Expanded Access Protocol for an Intermediate Size Population - RAVICTI for Byler Disease Temporarily not available University of Pittsburgh N/A 1969-12-31 Byler Disease is the result of a homozygous missense (G308V) mutation in the ATP8B1 gene. The disease is typically manifest in the first year of life on the basis of complications of cholestasis; common presentations include jaundice, poor growth, bleeding related to vitamin K deficiency, and/or weak bones related to vitamin D deficiency. Early management of Byler Disease is directed at nutritional issues which tend to be responsive to medical intervention, unlike the pruritus/scratching which remains a devastating problem. Progressive liver disease develops in Byler Disease and can lead to cirrhosis and end-stage liver disease. This is an open label expanded access protocol of RAVICTI in children with Byler Disease. The primary hypothesis is that the administration of RAVICTI in these children is feasible, well tolerated and safe. It is also hypothesized that RAVICTI treatment leads to an improvement in biochemical markers of liver disease and it may ameliorates or prevents the development of scratching behavior as a manifestation of pruritus attributed to the liver disease.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Ravicti

Condition Name

Condition Name for Ravicti
Intervention Trials
Byler Disease 2
Urea Cycle Disorder 2
Parkinson's Disease 1
Medium-chain Acyl-CoA Dehydrogenase (MCAD) Deficiency 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Ravicti
Intervention Trials
Urea Cycle Disorders, Inborn 3
Disease 3
Cholestasis, Intrahepatic 2
Parkinson Disease 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Ravicti

Trials by Country

Trials by Country for Ravicti
Location Trials
United States 27
Canada 1
Switzerland 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Ravicti
Location Trials
Pennsylvania 3
Ohio 2
New York 2
Minnesota 2
Maine 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Ravicti

Clinical Trial Phase

Clinical Trial Phase for Ravicti
Clinical Trial Phase Trials
Phase 4 2
Phase 3 1
Phase 1/Phase 2 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Ravicti
Clinical Trial Phase Trials
Not yet recruiting 2
Completed 2
No longer available 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Ravicti

Sponsor Name

Sponsor Name for Ravicti
Sponsor Trials
University of Pittsburgh 3
Horizon Therapeutics, LLC 2
Horizon Pharma Ireland, Ltd., Dublin Ireland 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Ravicti
Sponsor Trials
Other 7
Industry 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Colorcon
Johnson and Johnson
Boehringer Ingelheim
AstraZeneca
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.